BioLineRx Ltd. (BLRX)
TASE
Closed
Aug 24, 2026
Day's Range
1.5052 wk Range
1.10Overview - BLRX - BioLineRx Ltd.
Key Statistics
Valuation
Enterprise Value
4.18B
Price / Sales (TTM)
‪29.91‬
Price / Book
‪266.66‬
EV / EBITDA
‪-3.50‬
Profitability
Gross Margin
‪80.08%‬
Profit Margin
‪80.50%‬
Operating Margin
‪-629.76%‬
Return on Assets
‪-16.55%‬
Return on Equity
‪-46.72%‬
Ownership
Shares Outstanding
2.61B
Float
2.49B
Held by Insiders
‪2.86%‬
Held by Institutions
‪0.0020%‬
Price stats
Beta
‪0.71‬
50-Day Avg
‪1.51‬
200-Day Avg
‪1.51‬
Dividends
Payout Ratio
‪0.00%‬
Peers - BLRX - BioLineRx Ltd.
Peer Comparison
Compared with companies in Biotechnology listed on TASE.
- BLRXTASEBioLineRx Ltd.4.17BMarket Cap-46.67%52-week change—P/E (Trailing)‪80.50%‬Profit Margin
- AURATASEAura Investments Ltd.450.88BMarket Cap-41.71%52-week change17.71P/E (Trailing)‪12.50%‬Profit Margin
- ATRYTASEAtreyu Capital Markets Ltd.90.59BMarket Cap-28.54%52-week change7.98P/E (Trailing)‪96.43%‬Profit Margin
- BONSTASEBonus BioGroup Ltd.21.25BMarket Cap-22.84%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- BOLTTASEBiolight Life Sciences Ltd.2.36BMarket Cap-102.41%52-week change-143.43P/E (Trailing)‪0.00%‬Profit Margin
- BIOVTASEBio View Ltd.1.16BMarket Cap-169.82%52-week change28.00P/E (Trailing)‪-76.92%‬Profit Margin
Profile Summary - BLRX - BioLineRx Ltd.
About
BioLineRx Ltd. is a biopharmaceutical company that focuses on identifying, developing, and bringing to market novel therapeutics in the oncology space. The company's primary objective is to address significant unmet medical needs by advancing new drug candidates through clinical development phases toward…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
